Stockreport

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) [Yahoo! Finance]

Palatin Technologies, Inc.  (PTN) 
NASDAQ:AMEX Investor Relations: palatin.com/investors/overview
PDF biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database [Read more]